Repaglinide Tablets 2mg

Repaglinide Tablets 2 mg
  • Dosage: Repaglinide 2 mg
  • Packaging: 10tablets/blister*10/box
  • Shelf Life: 36months 

Click to add this item to cart.

Product Description

Product NameRepaglinide Tablets (Repaglinide 2mg Oral Tablets)
SpecificationEach tablet contains: Repaglinide 2mg
Dosage FormOral Tablet (for oral administration)
Active IngredientRepaglinide
Pharmacological ClassMeglitinide Insulin Secretagogue (Antidiabetic Agent)
Route of AdministrationOral administration (swallowed whole with water; take within 30 minutes before meals, typically 15 minutes before the meal). Skip the dose if the meal is skipped.
PackagingBlister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle
StorageStore below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze.
Shelf Life24 months (unopened)

Product Overview

Repaglinide Tablets is an oral preparation containing Repaglinide 2mg per tablet. Repaglinide is a meglitinide-class insulin secretagogue used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is a prandial glucose regulator that is taken before meals to stimulate insulin secretion and reduce postprandial blood glucose levels. The product is formulated as oral tablets for convenient dosing before each meal.

Repaglinide Tablets 2mg: What the Published Guidance Says

Human and analogue insulins alongside the oral hypoglycaemics and cardiorenal-metabolic agents added to the WHO Model List in its September 2025 revision.

Buyers usually settle three things before ordering Repaglinide Tablets 2mg: the pharmacopoeial monograph, the pack configuration, and the documents the destination authority will ask for.

  • The Model List details the insulin presentations and strengths Section 18.5.1 of the 24th WHO Model List (2025) lists human short-acting insulin as an injection solution of 40 IU/mL or 100 IU/mL in 10 mL vials and 100 IU/mL in 3 mL cartridges or pre-filled pens. Human intermediate-acting insulin is listed as an injection suspension in the same strengths, as compound insulin zinc suspension or isophane insulin. Long-acting and rapid-acting analogues are listed with glargine, degludec and detemir named among the therapeutic alternatives — a footnote notes that quality-assured biosimilars are included. WHO eEML — Medicines for diabetes
  • SGLT2 inhibitors are on the Model List Section 18.5.2 lists empagliflozin as a 10 mg and 25 mg tablet for type 2 diabetes mellitus, with canagliflozin and dapagliflozin named as therapeutic equivalents. WHO eEML — Medicines for diabetes
  • The scale of the access problem WHO reports that more than 800 million people were living with diabetes in 2022, with half going untreated, and that more than one billion people worldwide are affected by obesity with rates rising fastest in low- and middle-income countries. WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)

These points are quoted because they shape how Repaglinide Tablets 2mg is specified, labelled and purchased — including strength selection, pack size and the artwork wording. Confirm each one against the approved product information in your market before finalising a purchase order.

Repaglinide Tablets 2mg: Specification, Pack & Documentation Summary

Product NameRepaglinide Tablets (Repaglinide 2mg Oral Tablets)
SpecificationEach tablet contains: Repaglinide 2mg
Dosage FormOral Tablet (for oral administration)
Active IngredientRepaglinide
Pharmacological ClassMeglitinide Insulin Secretagogue (Antidiabetic Agent)
Route of AdministrationOral administration (swallowed whole with water; take within 30 minutes before meals, typically 15 minutes before the meal). Skip the dose if the meal is skipped.
StorageStore below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze.
Therapeutic groupDiabetes & Insulin — Diabetes & Insulin
ManufacturerSinophare Bio-technology Co., Ltd. (GMP, China)
Documentation suppliedCOA, HPLC/GC data, stability data, dossier package

The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Dapagliflozin 10mg Tablets, Canagliflozin 300mg Tablets, Empagliflozin 25mg Tablets, Ertugliflozin 15mg Tablets, Finerenone 20mg Tablets, Sotagliflozin 400mg Tablets, Mixed Protamine Human Insulin 30R, Insulin Glargine Injection 100IU/mL 3ml Cartridge.

How Repaglinide Tablets 2mg Is Tested and Released

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Repaglinide Tablets 2mg is released against the pharmacopoeial monograph named on your order (USP, EP, BP or CP). Where no monograph exists for the exact presentation, the specification is agreed with you in writing before manufacture and is attached to the certificate of analysis.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

Release testing on this presentation is built around:

  • Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
  • Testing for microbial limits and preservative efficacy (multi-dose presentations)
  • Testing for heavy metals and elemental impurities
  • Testing for packaging integrity and seal testing
  • Testing for description and identification
  • Testing for assay of the active substance

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

How Repaglinide Tablets 2mg Is Packed, Labelled and Shipped

  • Pack size: Blister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle. Non-standard pack sizes can be quoted against your artwork.
  • Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
  • Shelf life: 24 months (unopened). Stability data for the marketed pack is included in the dossier.
  • Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
  • Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.

Regulatory Support for Repaglinide Tablets 2mg

Sinophare Bio-technology Co., Ltd. holds DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. That registration identifies the legal manufacturer on the certificate of analysis, the GMP certificate and the documents filed with your national medicines authority.

  • Batch manufacturing and packaging records released for inspection on request during supplier audits.
  • Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
  • CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
  • Site Master File and GMP certificate for the manufacturing workshops.
  • Method validation, stability protocol and the shelf-life justification for the marketed pack.

This page describes Repaglinide Tablets 2mg as a product of the medicines for diabetes listed in the WHO Model List family. A WHO or national listing is a supply-context fact, not an approval in your market; marketing authorisation remains specific to each country.

Questions We Are Asked About Repaglinide Tablets 2mg

What pack size is available for Repaglinide Tablets 2mg?

The reference pack is Blister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle. Non-standard blister, bottle and carton configurations are quoted against your artwork, matched to the stability data already held for the presentation.

What documentation comes with a shipment of Repaglinide Tablets 2mg?

Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 24 months.

Does the batch documentation for Repaglinide Tablets 2mg support a registration filing?

Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 24 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.

How is insulin shipped?

Under temperature-controlled conditions with shipment temperature records. Confirm the exact cold-chain specification required for your market before ordering.

Can you support an insulin registration dossier?

Yes — we provide DMF and dossier packages with registration support documents. DML Number Jin20160068 covers medicines production.

Companion Products — Diabetes & Insulin

Browse the full Diabetes & Insulin range; all Tablets; the complete product catalogue.

Request a Quotation for Repaglinide Tablets 2mg

Send the specification, pack size, quantity and destination market for Repaglinide Tablets 2mg 2mg and we will confirm availability, lead time and documentation. Tender quantities and registration samples are handled on the same quotation.

Request a quotation

Sources & Regulatory Notes

Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.

<< return to products